Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
VMF
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 5 Aminolaevulinate
2. 5 Aminolevulinate
3. 5-aminolaevulinate
4. 5-aminolevulinate
5. Acid Hydrochloride, Aminolevulinic
6. Acid, Aminolevulinic
7. Acid, Delta-aminolevulinic
8. Aminolevulinic Acid
9. Aminolevulinic Acid Hydrochloride
10. Delta Aminolevulinic Acid
11. Delta-aminolevulinic Acid
12. Hydrochloride, Aminolevulinic Acid
13. Levulan
1. 5451-09-2
2. Aminolevulinic Acid Hydrochloride
3. Levulan
4. 5-amino-4-oxopentanoic Acid Hydrochloride
5. Levulan Kerastick
6. 5-aminolevulinic Acid Hcl
7. Gliolan
8. Aminolevulinic Acid Hcl
9. Ameluz
10. Delta-aminolevulinic Acid Hydrochloride
11. Mfcd00012869
12. Alaglio
13. Gleolan
14. Alabel
15. Pentanoic Acid, 5-amino-4-oxo-, Hydrochloride
16. 5-aminolevulinic Acid, Hcl
17. 5-aminolevulinic Acid (hydrochloride)
18. 5-aminolevulinate Hydrochloride
19. 5-ala
20. Nsc-18509
21. V35kbm8jgr
22. 5-aminolevulinic Acid Hydrochloride Salt
23. .delta.-aminolevulinic Acid Hydrochloride
24. 5-amino-4-oxopentanoic Acid;hydrochloride
25. Npc-07
26. (4-carboxy-2-oxobutyl)azanium;chloride
27. 5-amino-4-oxopentanoic Acid Hcl
28. Aminolevulinic Acid Hydrochloride [usan]
29. Ncgc00095111-01
30. Dsstox_cid_25914
31. Dsstox_rid_81222
32. Dsstox_gsid_45914
33. 5-amino-4-oxopentanoic Acid Hydrochloride;5-amino-4-oxopentanoic Acid
34. Cas-5451-09-2
35. 5-amino-levulinic Acid Hydrochloride
36. 5-aminolevulinic Acid Hydrochloride, >=97.0% (at)
37. Alacare
38. Ala Hydrochloride
39. Einecs 226-679-5
40. Gleolan (tn)
41. Levulan (tn)
42. Ameluz (tn)
43. Nsc 18509
44. Ala Hcl
45. Ala-pdt
46. Levulinic Acid, 5-amino-, Hydrochloride
47. Unii-v35kbm8jgr
48. 5-amino-3-oxopentanoic Acid (hydrochloride)
49. 5-aminolevulinic Acid.hcl
50. Ala;5-ala
51. Pentanoic Acid, Hydrochloride
52. 5-amino-4-keto-valeric Acid
53. Schembl192308
54. Spectrum1504184
55. Chembl1200582
56. Dtxsid5045914
57. Chebi:132969
58. Hms1922f13
59. Pd-p-506-a
60. Pharmakon1600-01504184
61. 5 Ala Hcl (trivial Name)
62. Act05562
63. Bcp02161
64. Hy-n0305
65. Nsc18509
66. 5-amino Levulinic Acid Hydrochloride
67. Tox21_111426
68. Ccg-39079
69. Nsc758687
70. Akos015904495
71. Aminolevulinic Acid Hcl [inci]
72. Tox21_111426_1
73. Ac-4252
74. Bcp9000174
75. Gs-3020
76. Nsc-758687
77. 4-carboxy-2-oxobutan-1-aminium Chloride
78. 5-aminolevulinic Acid Hydrochloride, Gmp
79. Ncgc00095111-02
80. Ncgc00095111-03
81. Ncgc00178086-03
82. 5451-09-2 (hcl)
83. Sy017972
84. Db-005367
85. 5-aminolevulinic Acid Hydrochloride, >=98%
86. A0325
87. Am20100341
88. S2553
89. Sw218068-2
90. Aminolevulinic Acid Hydrochloride (jan/usan)
91. A-6100
92. A-6102
93. A-6103
94. A-6105
95. Aminolevulinic Acid Hydrochloride [jan]
96. D02908
97. Aminolevulinic Acid Hydrochloride [mart.]
98. 451a092
99. Aminolevulinic Acid Hydrochloride [usp-rs]
100. Aminolevulinic Acid Hydrochloride [who-dd]
101. .delta.-aminolevulinic Acid Hydrochloride [mi]
102. 5-aminolevulinic Acid Hydrochloride [ema Epar]
103. Aminolevulinic Acid Hydrochloride [orange Book]
104. Q27291473
105. Aminolevulinic Acid Hydrochloride [usp Monograph]
106. 0c1e43db-1221-4963-bfa4-18d3170000a4
107. 5-aminolevulinic Acid Hydrochloride, Particle Size < 0.25 Mm
108. Aminolevulinic Acid Hydrochloride Component Of Sonala001
109. Aminolevulinic Acid Hydrochloride Component Of Sonala-001
110. 5-aminolevulinic Acid Hydrochloride, Bioreagent, Suitable For Cell Culture, Powder, >=98%
111. Aminolevulinic Acid Hcl; Aminolevulinic Acid Hydrochloride;ala; 5-ala;aminolevulinic Acid
112. Aminolevulinic Acid Hydrochloride, United States Pharmacopeia (usp) Reference Standard
Molecular Weight | 167.59 g/mol |
---|---|
Molecular Formula | C5H10ClNO3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 4 |
Exact Mass | 167.0349209 g/mol |
Monoisotopic Mass | 167.0349209 g/mol |
Topological Polar Surface Area | 80.4 Ų |
Heavy Atom Count | 10 |
Formal Charge | 0 |
Complexity | 121 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Levulan |
PubMed Health | Aminolevulinic Acid (On the skin) |
Drug Classes | Photosensitizing Agent |
Active Ingredient | Aminolevulinic acid hydrochloride |
Dosage Form | Solution |
Route | Topical |
Strength | 20% |
Market Status | Prescription |
Company | Dusa |
2 of 2 | |
---|---|
Drug Name | Levulan |
PubMed Health | Aminolevulinic Acid (On the skin) |
Drug Classes | Photosensitizing Agent |
Active Ingredient | Aminolevulinic acid hydrochloride |
Dosage Form | Solution |
Route | Topical |
Strength | 20% |
Market Status | Prescription |
Company | Dusa |
Treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 2; see section 5. 1) and of field cancer ization in adults.
Treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults.
Gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (World Health Organization grade III and IV).
Photosensitizing Agents
Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. (See all compounds classified as Photosensitizing Agents.)
L01XD04
L01XD04
Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29376
Submission : 2015-05-27
Status : Active
Type : II
Available Reg Filing : ASMF, CH, TR |
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9972
Submission : 1992-11-25
Status : Active
Type : II
NDC Package Code : 51504-0005
Start Marketing Date : 1992-11-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Daewoong Pharmaceutical Co., Ltd.
Registration Date : 2007-09-28
Registration Number : 43-2-ND
Manufacturer Name : Sochinaz SA
Manufacturer Address : Route du Simplon 22 CH-1895 Vionnaz, Switzerland
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24359
Submission : 2010-11-12
Status : Active
Type : II
Registration Number : 224MF10095
Registrant's Address : Heraeusstr. 12-14; 63450 Hanau; Germany
Initial Date of Registration : 2012-04-27
Latest Date of Registration : --
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23711
Submission : 2010-04-06
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24562
Submission : 2010-12-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17844
Submission : 2004-11-15
Status : Inactive
Type : II
Registration Number : 229MF10010
Registrant's Address : 2-2 Nihonbashi Honcho 4-chome, Chuo-ku, Tokyo
Initial Date of Registration : 2017-01-18
Latest Date of Registration : --
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Ameluz (5-aminolevulinic acid hydrochloride) is a topical gel that acts as a photosensitizing agent during photodynamic therapy. It is used primarily for the treatmentsuperficial basal cell carcinoma.
Lead Product(s): Aminolevulinic Acid HCl
Therapeutic Area: Oncology Brand Name: Ameluz
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2024
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biofrontera Completes Database Lock in Ameluz® PDT Study for sBCC
Details : Ameluz (5-aminolevulinic acid hydrochloride) is a topical gel that acts as a photosensitizing agent during photodynamic therapy. It is used primarily for the treatmentsuperficial basal cell carcinoma.
Brand Name : Ameluz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 14, 2024
Details:
Ameluz is the only PDT photosensitizer indicated by the FDA for both lesion-directed and field-directed treatment of Actinic Keratosis.
Lead Product(s): Aminolevulinic Acid HCl
Therapeutic Area: Dermatology Brand Name: Ameluz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2024
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA OKs Triple-Tube Use of Ameluz Gel for Skin Cancer Treatment
Details : Ameluz is the only PDT photosensitizer indicated by the FDA for both lesion-directed and field-directed treatment of Actinic Keratosis.
Brand Name : Ameluz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 07, 2024
Details:
The Company intends to fund ongoing activities related to expediting the development and approval of additional indications for Ameluz (aminolevulinic acid hydrochloride) to treat actinic keratoses.
Lead Product(s): Aminolevulinic Acid HCl
Therapeutic Area: Dermatology Brand Name: Ameluz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Roth Capital Partners
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 23, 2024
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Roth Capital Partners
Deal Size : $16.0 million
Deal Type : Private Placement
Biofrontera Inc. Announces Closing Of Private Placement Of Up To $16.0 Million
Details : The Company intends to fund ongoing activities related to expediting the development and approval of additional indications for Ameluz (aminolevulinic acid hydrochloride) to treat actinic keratoses.
Brand Name : Ameluz
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 23, 2024
Details:
SONALA-001 (aminolevulinic acid) is a porphyrin precursor and optical imaging agent. The mechanism of action of aminolevulinic acid is as a fluorescence contrast activity.
Lead Product(s): Aminolevulinic Acid HCl
Therapeutic Area: Oncology Brand Name: SONALA-001
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SONALA-001 (aminolevulinic acid) is a porphyrin precursor and optical imaging agent. The mechanism of action of aminolevulinic acid is as a fluorescence contrast activity.
Brand Name : SONALA-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 08, 2023
Details:
AMELUZ® (aminolevulinic acid hydrochloride) topical gel, 10%, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED® lamp, is indicated for lesion-directed and field-directed treatment of actinic keratoses.
Lead Product(s): Aminolevulinic Acid HCl
Therapeutic Area: Dermatology Brand Name: Ameluz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic ...
Details : AMELUZ® (aminolevulinic acid hydrochloride) topical gel, 10%, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED® lamp, is indicated for lesion-directed and field-directed treatment of actinic keratoses.
Brand Name : Ameluz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 21, 2022
Details:
AMELUZ (aminolevulinic acid hydrochloride) topical gel, 10%, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED® lamp, is indicated for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity.
Lead Product(s): Aminolevulinic Acid HCl
Therapeutic Area: Dermatology Brand Name: Ameluz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent
Details : AMELUZ (aminolevulinic acid hydrochloride) topical gel, 10%, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED® lamp, is indicated for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moder...
Brand Name : Ameluz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 06, 2022
Details:
Ameluz (Aminolevulinic Acid Hydrochloride) is utilized along with photodynamic therapy (PDT) provided by the Company’s proprietary lamp devices to form Ameluz®-PDT.
Lead Product(s): Aminolevulinic Acid HCl
Therapeutic Area: Dermatology Brand Name: Ameluz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ameluz (Aminolevulinic Acid Hydrochloride) is utilized along with photodynamic therapy (PDT) provided by the Company’s proprietary lamp devices to form Ameluz®-PDT.
Brand Name : Ameluz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 24, 2022
Details:
The new funds will aid to expand the market presence and strategic position. Together with broadening the product label through three clinical trials running in parallel with licensing partner, this will unravel the enormous market potential Ameluz® has long term.
Lead Product(s): Aminolevulinic Acid HCl
Therapeutic Area: Dermatology Brand Name: Ameluz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Roth Capital Partners
Deal Size: $9.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 19, 2022
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Roth Capital Partners
Deal Size : $9.4 million
Deal Type : Private Placement
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
Details : The new funds will aid to expand the market presence and strategic position. Together with broadening the product label through three clinical trials running in parallel with licensing partner, this will unravel the enormous market potential Ameluz® has...
Brand Name : Ameluz
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 19, 2022
Details:
AMELUZ (aminolevulinic acid hydrochloride) topical gel, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED® lamp, is indicated for lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on face and scalp.
Lead Product(s): Aminolevulinic Acid HCl
Therapeutic Area: Dermatology Brand Name: Ameluz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®
Details : AMELUZ (aminolevulinic acid hydrochloride) topical gel, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED® lamp, is indicated for lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate sever...
Brand Name : Ameluz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 21, 2022
Details:
Ameluz® is Biofrontera’s first FDA-approved flagship prescription drug is used in combination with the RhodoLED® lamp series for the treatment of Actinic Keratoses, and the topical antibiotic drug Xepi®.
Lead Product(s): Aminolevulinic Acid HCl
Therapeutic Area: Dermatology Brand Name: Ameluz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ameluz® is Biofrontera’s first FDA-approved flagship prescription drug is used in combination with the RhodoLED® lamp series for the treatment of Actinic Keratoses, and the topical antibiotic drug Xepi®.
Brand Name : Ameluz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 17, 2022
CAS Number : 14794-31-1
End Use API : Aminolevulinic Acid HCl
About The Company : Bhushilpa Chemicals was set up in 2001 with a vision to develop, manufacture and market specialty chemicals and drug intermediates through implementation of qu...
CAS Number : 1490-25-1
End Use API : Aminolevulinic Acid HCl
About The Company : Bhushilpa Chemicals was set up in 2001 with a vision to develop, manufacture and market specialty chemicals and drug intermediates through implementation of qu...
Regulatory Info :
Registration Country : Sweden
aminolevulinic acid hydrochloride
Brand Name : Ameluz
Dosage Form : GEL
Dosage Strength : 78 MG / G
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info : Prescription
Registration Country : Canada
AMINOLEVULINIC ACID HYDROCHLORIDE
Brand Name : LEVULAN KERASTICK
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 20%
Packaging : 1.5ML
Approval Date :
Application Number : 2243933
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info :
Registration Country : Sweden
aminolevulinic acid hydrochloride
Brand Name : Alacare
Dosage Form : MEDICAL PATCH
Dosage Strength : 8 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Switzerland
Aminolaevulinatis hydrochloridum
Brand Name : Alacare
Dosage Form : Pfl
Dosage Strength : 8mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Aminolaevulinatis hydrochloridum
Brand Name : Alacare
Dosage Form : Pfl
Dosage Strength : 8mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Ameluz
Dosage Form : Gel
Dosage Strength : 78mg/g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info : RX
Registration Country : USA
AMINOLEVULINIC ACID HYDROCHLORIDE
Brand Name : GLEOLAN
Dosage Form : FOR SOLUTION;ORAL
Dosage Strength : 1.5GM/VIAL
Packaging :
Approval Date : 2017-06-06
Application Number : 208630
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
AMINOLEVULINIC ACID HYDROCHLORIDE
Brand Name : LEVULAN
Dosage Form : SOLUTION;TOPICAL
Dosage Strength : 20%
Packaging :
Approval Date : 1999-12-03
Application Number : 20965
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Sweden
aminolevulinic acid hydrochloride
Brand Name : Gliolan
Dosage Form : POWDER FOR ORAL SOLUTION
Dosage Strength : 30 MG / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Gliolan
Dosage Form : Powder for potion, resolution
Dosage Strength : 30 mg/ml
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
RLD : Yes
TE Code :
AMINOLEVULINIC ACID HYDROCHLORIDE
Brand Name : AMELUZ
Dosage Form : GEL;TOPICAL
Dosage Strength : 10%
Approval Date : 2016-05-10
Application Number : 208081
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
AMINOLEVULINIC ACID HYDROCHLORIDE
Brand Name : GLEOLAN
Dosage Form : FOR SOLUTION;ORAL
Dosage Strength : 1.5GM/VIAL
Approval Date : 2017-06-06
Application Number : 208630
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
AMINOLEVULINIC ACID HYDROCHLORIDE
Brand Name : LEVULAN
Dosage Form : SOLUTION;TOPICAL
Dosage Strength : 20%
Approval Date : 1999-12-03
Application Number : 20965
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?